A new artificial intelligence tool that analyzes vast amounts of medical information, including MRI data, earned recent praise for improving prostate cancer care, according to the authors of a recent study.
Case Western Reserve researchers and a handful of top medical centers teamed up to develop and validate the platform, known as RadClip. They tested it on MRI scans taken from nearly 200 patients treated across the Cleveland Clinic, Mount Sinai Hospital, University Hospitals and the Hospital of the University of Pennsylvania.
In addition to accurately predicting the risk of cancer returning, it also spotted subtle differences inside and outside tumor regions on preoperative MRI scans. With further validation, researchers believe RadClip could become a valuable treatment decision tool.
“We’re bringing together and connecting a variety of information, from radiologic scans like MRI to digitized pathology specimen slides and genomic data, for providing a more comprehensive characterization of the disease,” senior author Anant Madabhushi, PhD, director of Case Western’s Center for Computational Imaging and Personalized Diagnostics, said in a statement.
The team also noted their platform outperformed well-known prognostic tools, including Cancer of the Prostate Risk Assessment scoring and the genomic-based Decipher Prostate Cancer Test.
“Genomic-based tests cost several thousand dollars and involve destructive testing of the tissue,” Madabhushi added Thursday. “Prognostic predictions from an MRI scan provide a non-invasive method for making both short-term and long-term decisions on treatment.”